Study guide
4.2 Ectopic Pregnancy: Diagnosis & Management
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
4.2 Ectopic Pregnancy: Diagnosis & Management
Key Takeaways Explain This Topic AI
The ampulla is the most common implantation site at about 70 percent, while interstitial ectopics rupture later at 12 to 16 weeks with catastrophic hemorrhage from uterine artery anastomoses.
ACOG now advises a conservative discriminatory threshold of 3,500 mIU/mL before concluding a pregnancy of unknown location is not intrauterine, rather than the historic 1,500 to 2,000 mIU/mL.
Methotrexate candidacy requires hemodynamic stability, hCG below 5,000 mIU/mL, an adnexal mass under 3.5 to 4.0 cm, no embryonic cardiac activity, and normal renal, hepatic, and hematologic function.
Single-dose methotrexate success is defined as a 15 percent or greater fall in hCG between day 4 and day 7; hCG may legitimately rise between day 1 and day 4 as trophoblast lyses.
Laparoscopic salpingectomy is preferred over salpingostomy because it eliminates persistent trophoblast without materially reducing future fertility.
Last updated: September 2026
Ectopic Pregnancy: Triage, Diagnostics & Management
Ectopic pregnancy occurs when a blastocyst implants outside the endometrial cavity of the uterus. It accounts for 1% to 2% of all pregnancies but causes 6% of all pregnancy-related maternal deaths, primarily due to catastrophic hemorrhage following tubal rupture.
Anatomic Sites and Risk Factors
Anatomic Locations: Over 95% of ectopic pregnancies implant in the fallopian tube. Specific tubal distributions include the ampullary segment (70%, most common), isthmus (12%), fimbria (11%), and interstitial/cornual segment (2% to 3%). Interstitial ectopic pregnancies implant in the myometrial segment of the fallopian tube; rupture here occurs later (12–16 weeks) and results in massive, rapidly fatal hemorrhage due to the proximity of the uterine artery anastomosis.
Major Risk Factors: Prior ectopic pregnancy (3- to 8-fold increased risk), history of salpingitis or pelvic inflammatory disease (PID), prior tubal reconstructive surgery or tubal sterilization, assisted reproductive technology (ART), current intrauterine device (IUD) in situ, and maternal tobacco smoking.
Diagnostic Algorithm: Quantitative hCG & Ultrasound Discriminatory Zone
The clinical triad of ectopic pregnancy comprises amenorrhea, vaginal bleeding, and unilateral pelvic pain . However, up to 50% of patients are asymptomatic or present with non-specific symptoms. [ Hemodynamically Stable Early Pregnancy Bleeding/Pain ]
- │
- Quantitative Serum β-hCG & TVUS
- │
- ┌──────────────────────────────┴──────────────────────────────┐
- ▼ ▼
- [ β-hCG ≥ Discriminatory Zone ] [ β-hCG < Discriminatory Zone ]
- (1,500 – 2,000 mIU/mL) (e.g., 500 mIU/mL)
- │ │
TVUS Findings: TVUS Findings:
- ┌──────────┴──────────┐ ┌──────────────┴──────────────┐
- ▼ ▼ ▼ ▼
- Intrauterine Sac No Intrauterine Sac Indeterminate (PUL) Definite Ectopic
- (Normal IUP) (Ectopic Highly Presumed) Serial β-hCG in 48h Mass / Adnexal FHR
- │ │ │
- Candidate for Expected Rise ≥35-53% Candidate for MTX
- Methotrexate vs If rises normally: IUP vs Laparoscopy
- Laparoscopy If plateaus/falls: Nonviable
Transvaginal Ultrasound (TVUS) Discriminatory Zone: The discriminatory zone is the serum concentration of beta-hCG above which an intrauterine gestational sac must reliably be visualized on TVUS if a viable singleton intrauterine pregnancy is present. Most centers establish this threshold at 1,500 to 2,000 mIU/mL (or up to 3,500 mIU/mL to prevent misdiagnosis of viable IUPs). If the beta-hCG exceeds 2,000 mIU/mL and no intrauterine sac is visualized, ectopic pregnancy must be strongly suspected.
Pregnancy of Unknown Location (PUL): When the beta-hCG is below the discriminatory zone and TVUS is indeterminate, serial quantitative beta-hCG levels are obtained 48 hours apart . A viable normal intrauterine pregnancy typically demonstrates an increase in beta-hCG of at least 35% to 53% over 48 hours. An abnormal, plateauing, or slow rise indicates an abnormal pregnancy (either nonviable intrauterine pregnancy or ectopic pregnancy).
- Medical vs. Surgical Management Protocols
- 1. Methotrexate Medical Therapy
Methotrexate is a folic acid antagonist that competitively binds to dihydrofolate reductase, inhibiting DNA synthesis and cell proliferation in rapidly dividing trophoblastic tissue.
Absolute Inclusion Criteria:
- Hemodynamically stable with no signs of active intraperitoneal hemorrhage or rupture
- Serum quantitative beta-hCG <5,000 mIU/mL (success rate >90%)
- Transvaginal ultrasound demonstrates an adnexal mass <3.5 to 4.0 cm in greatest diameter
- Absence of embryonic cardiac activity on ultrasound
- Patient is willing and able to comply with extended post-treatment surveillance
- Normal baseline liver transaminases, serum creatinine, and complete blood count
Contraindications: Hemodynamic instability, renal impairment, active hepatic disease, pulmonary disease, active peptic ulcer disease, immunodeficiency, ongoing breastfeeding, or coexisting viable intrauterine pregnancy.
Single-Dose Protocol: 50 mg/m² body surface area (BSA) IM on Day 1. Quantitative serum beta-hCG is measured on Day 4 and Day 7 .
It is expected that hCG may rise between Day 1 and Day 4 as trophoblast cells undergo lysis.
A successful response is defined as a ≥15% decline in beta-hCG concentration between Day 4 and Day 7.
If beta-hCG declines by ≥15%, monitor beta-hCG weekly until undetectable (<5 mIU/mL).
If beta-hCG declines by <15% between Day 4 and Day 7, administer a second dose of methotrexate (50 mg/m² IM) on Day 7 or perform surgical laparoscopy.
2. Surgical Management
Indications: Hemodynamic instability (tachycardia, hypotension, syncope), signs of tubal rupture or acute hemoperitoneum (peritoneal rebound, guarding, shoulder tip pain), failed medical therapy, adnexal mass ≥4 cm, or presence of fetal cardiac motion.
Procedure: Laparoscopic salpingectomy (complete excision of the involved fallopian tube) is preferred over salpingostomy (linear incision over the tube and evacuation of products), as salpingectomy reduces the risk of persistent trophoblast tissue without significantly diminishing future fertility rates.
Important
Which discriminatory-zone number should you use? Historic practice used 1,500–2,000 mIU/mL, and many local protocols still cite it. ACOG now advises a conservative threshold of 3,500 mIU/mL before concluding that a pregnancy of unknown location is not intrauterine, precisely because acting at the lower number has led to interruption of viable, desired intrauterine pregnancies. In a stable patient the safe practice is the same either way: repeat the quantitative hCG and the transvaginal scan rather than treat on a single value. Reserve immediate intervention for the unstable patient or for a definitive sonographic ectopic (extrauterine yolk sac, embryo, or cardiac activity).